SOX9 and neoplasm: CMD‐BHQ3‐PTL/DOX@RBCm efficiently inhibited CRC cells in vitro and demonstrated remarkable anti‐tumor effects in vivo, providing novel insights for nanomedicine optimization and deepening our understanding of the role of the Hippo/YAP1/SOX9 pathway in CRC development.[48, 49]